In contrast, the chronic myeloid leukemia (CML) cell K562 has very low endogenous AQP9 and thus harbors the least sensitivity or efficacy to As2O3 treatment [15]. Here, AQP9 is linked to chronic myelogenous leukemia, BCR-ABL1 positive.